Skip to main content
Fig. 6 | Molecular Cancer

Fig. 6

From: Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison

Fig. 6

Efficacy, adverse events, and survival outcome of bispecific antibody treatment and ICI combination therapies in patients with Melanoma, nasopharyngeal cancer, and renal cell carcinoma. A histogram of antitumor activity (a), a forest plot of survival outcomes (b), incidence of grade ≥ 3 TRAEs, including major components (c) and skin toxicity (d) of BSABs and ICIs combination therapies in patients with melanoma. Rela, Relatlimab (anti- LAG-3). A histogram of antitumor activity (e) and common adverse effects components, including incidence of grade ≥ 3 TRAEs (f) of BSABs in patients with nasopharyngeal cancer. A histogram of antitumor activity (g), a forest plot of survival outcomes (h) and incidence of grade ≥ 3 TRAEs, including components (i) of ICIs combination therapies in patients with renal cell carcinoma. ITT, intent-to-treat patients; I/P risk, patients with intermediate/poor-risk disease. The ORR, defined as a sum of CR and PR. A bar with a value of 0 means not mentioned in the article

Back to article page

Molecular Cancer

ISSN: 1476-4598